Targeting Complex Solid Oral and Alternative Dosage Form Generic Products

On May 7, 2018, Impax Laboratories, Inc. combined with Amneal Pharmaceuticals, Inc. (NYSE:AMRX) to create a dynamic company powered by a robust U.S. generics business and growing branded franchise. Today, we are working to integrate our business into the new Amneal and are excited about our future as one company.

Amneal + Impax Generics R&D

We are committed to expanding our Generics division by targeting complex solid oral and alternative dosage form Abbreviated New Drug Applications (ANDAs) with high-value, difficult to develop, first-to-file or first-to-market product opportunities. Our combined development capabilities are industry-leading and span all dosage forms, including complex oral solids, injectables, ophthalmics, liquids, topicals and transdermals.

The Amneal + Impax combined Generics pipeline is currently one of the industry’s largest, including more than 280 products filed with the FDA or in development*. This pipeline includes products across a broad range of therapeutic areas including cardiovascular, central nervous system/pain, oncology, inflammation, anti-infective, dermatology, endocrinology, diabetes, rhinology, urology, and hematology, among others.

We are also excited about our work to bring patients more affordable biologic therapy options through our growing biosimilars program, which today includes one filed product and one near-term filing opportunity.

 

*As of April 16, 2018